Traditional Chinese herbal medicine (TCM) has been used in Chinese society for more than 5,000 years to treat diseases from inflammation to cancer. Here, we report the case of nine living AIDS patients in the age range of 51 to 67 who were treated with either a unique formula of TCM alone from 2001 to 2009 or the TCM from 2001 to 2006 and then switched to occasional antiretroviral therapy. Surprisingly, the viral loads of eight patients were at undetectable levels on June 28, 2016, while the remaining patient had a low viral load of 29 copies/ml. The CD4
A ntiretroviral therapy (ART), a combination of three or more small molecule inhibitors, has been widely used to treat HIV/AIDS patients since the 1990s. Although highly effective, ART is known to cause severe and long-term side effects to patients. Interestingly, some of the side effects associated with ART can be reduced by traditional Chinese herbal medicine (TCM). 1 TCM also enhances patients' immune functions and reduces AIDS symptoms. 1 However, there are no reports on long-term survival of AIDS patients treated with only TCM. Here, we report a case series of nine living AIDS patients in the age range of 51 to 67 (Table 1) who have been infected with HIV-1 for 21 to 23 years and were treated with either a unique formula of TCM alone or the TCM for several years before switching to occasional ART. The TCM contains combined extracts from 13 different plants, including Astragalus, Skullcap, and Ginseng (Experiment Methods in Supplementary Data; Supplementary Data are available online at www.liebertpub.com/aid). Through HPLC-based fractionation and drug screening methods, others have previously discovered that some of these plants contain polysaccharides, protein components, alkaloids, lactones, and terpenes, which directly inhibit the enzymatic activities of recombinant HIV-1 protease, reverse transcriptase, and integrase, as well as the interaction between HIV-1 gp120 and immobilized CD4 receptors.
1,2 The TCM also contains known natural products, which boost the immune system, cytokine stimulation, or other pathways in patients.
1,2 For example, shikonin can decrease CCR5 mRNA and the expression of CCR5, a chemokine receptor commonly utilized by HIV to enter host immunological cells. 2 The case series of the TCM was administered by a small Chinese company, which bankrupted by the end of 2009. The enrolled patients, who are poor peasants from an ''AIDS Village'' in Anhui Province, China, contracted HIV-1 sometime between 1993 and 1995 through commercial plasma donation 3 and were officially diagnosed at Guangzhou Center for Disease Control and Prevention (Guangzhou, China) on December 19, 2002. At that time, there were at least 42 HIV-infected people in the same village but few believed that the TCM could effectively treat AIDS. Accordingly, only nine patients were willing to participate in the case series. By late 2001, all of the nine randomly selected patients showed typical AIDS symptoms after being infected by HIV-1 for 6 to 8 years (Supplementary Table S1 Table S1 ). Interestingly, AIDS symptoms in all patients were improved after 3 months of the TCM treatment, and almost disappeared after 1 year of the TCM treatment (Supplementary Table S1 ). The TCM treatment was well tolerated by all patients and displayed little clinical toxicity. While most medical data collected in the case series were unfortunately lost due to the bankruptcy of the company, several recovered plasma viral loads measured from 2003 to 2006 showed significant decreases and varied from patient to patient (Table 1 and Supplementary Figs. S1 and S2 ). Table 1 also shows that only Patient C had a viral load of slightly lower than 2,000 copies/ ml on July 24, 2003 after treatment with the TCM for 22 months. It is likely that all nine patients had much higher viral loads than 2,000 copies/ml before they were on the TCM. This disqualifies them from being considered as rare ''viremic controllers,'' who are defined as having viral loads less than 2,000 copies/ml over time with a low prevalence rate of 3.34% in HIV-infected patients. 5 Unexpectedly, the viral loads of eight patients were at undetectable levels as measured through COBAS AmpliPrep/TaqMan96 of Roche Molecular Systems (detection limit: 20 copies/ml) on June 28, 2016, while Patient E had a nearly undetectable viral load of 29 copies/ml (Table 1) . Furthermore, CD4 + counts (170-592 cells/ll) and CD4 + /CD8 + ratios (0.21-0.90) of the patients (Table 1 and Supplementary Fig. S3 ) are promising, although below the ranges for uninfected healthy adults. 6, 7 In comparison, a randomized clinical trial with ART on 898 US patients (ACTG 384) showed that the median CD4
+ count increased from 270 cells/ml pre-ART to an estimated 532 cells/ml seven years after starting ART in analyses ignoring treatment discontinuations. 8 Consistent with our findings, that clinical trial (ACTG 384) also revealed that a substantial percentage of the patients starting ART at low CD4 + counts still had low CD4 + counts after 7 years on ART. 8 Taken together, the optimistic T cell parameters and, more importantly, the extremely low viral loads presented in this case series study (Table 1) Table S1 ), yet, survived more than 15 years after AIDS onset. In contrast, without medical treatment, 82% of 294,662 patients in a published meta-analysis progressed from AIDS onset to AIDS-related deaths within 6 years. 6 Consistently, more than 30 HIV-infected patients in the same ''AIDS Village'' as Patients A-D died from AIDS between 1999 and 2003. Notably, none of these deceased patients took the TCM or any form of ART, which were inaccessible to poor Chinese peasants at that time.
However, unlike randomized controlled clinical trials, there was not a control patient group who took a proper placebo during this case series. In addition, the case series has a small sample size and eight of the nine enrolled patients are married couples. The TCM was neither randomly administered nor quantitatively monitored.
The case series data presented here, although incomplete and uncontrolled, demonstrate the promise of the TCM. Therefore, the TCM merits further and more rigorous evaluation through biochemical and biological studies, animal model testing, and randomized controlled clinical trials.
1 It would also be important to monitor the ART levels in the control group and patient cohorts to verify patient compliance of therapeutic regimens during future clinical investigation. If validated through these rigorous tests, the TCM can be utilized as a cost-effective HIV/AIDS treatment alone or in combination with ART, potentially contributing to a strategy for functional cure. 
